Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;20(12):770-782.
doi: 10.1038/s41584-024-01179-5. Epub 2024 Nov 7.

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus

Affiliations
Review

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus

Thomas Dörner et al. Nat Rev Rheumatol. 2024 Dec.

Abstract

Emerging evidence indicates that memory B cells are dysfunctional in systemic lupus erythematosus (SLE). They are hyporesponsive to signalling through the B cell receptor (BCR) but retain responsiveness to Toll-like receptor (TLR) and type I interferon signalling, as well as to T cell-mediated activation via CD40-CD154. Chronic exposure to immune complexes of ribonucleoprotein (RNP)-specific autoantibodies and TLR-engaging or BCR-engaging cargo is likely to contribute to this partially anergic phenotype. TLR7 or TLR8 signalling and the resulting production of type I interferon, as well as the sustained activation by bystander T cells, fuel a positive feedforward loop in memory B cells that can evade negative selection and permit preferential expansion of anti-RNP autoantibodies. Clinical trials of autologous stem cell transplantation or of B cell-targeted monoclonal antibodies and chimeric antigen receptor (CAR) T cells have correlated replenishment of the memory B cell population with relapse of SLE. Moreover, the BCR hyporesponsiveness of memory B cells might explain the failure of non-depleting B cell-targeting approaches in SLE, including BTK inhibitors and anti-CD22 monoclonal antibodies. Thus, targeting of dysfunctional memory B cells might prove effective in SLE, while also avoiding the adverse events of broad-spectrum targeting of B cell and plasma cell subsets that are not directly involved in disease pathogenesis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: T.D. declares honoraria for scientific advice from Abelzeta, BMS, Janssen, Novartis, Roche/GNE and UCB, and fees for clinical studies (paid to the university) by BMS, Novartis, Eli Lilly & Company, Janssen and Roche. P.E.L. is co-founder of AMPEL Biosolutions and an adviser to Abelzeta.

Similar articles

Cited by

References

    1. Akiyama, M., Alshehri, W., Yoshimoto, K. & Kaneko, Y. T follicular helper cells and T peripheral helper cells in rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 82, 1371–1381 (2023). - PubMed - DOI
    1. Giesecke, C. et al. Simultaneous presence of non- and highly mutated keyhole limpet hemocyanin (KLH)-specific plasmablasts early after primary KLH immunization suggests cross-reactive memory B cell activation. J. Immunol. 200, 3981–3992 (2018). - PubMed - DOI
    1. Giesecke, C. et al. Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J. Immunol. 192, 3091–3100 (2014). - PubMed - DOI
    1. Dorner, T., Giesecke, C. & Lipsky, P. E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 13, 243 (2011). - PubMed - PMC - DOI
    1. Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12, 232–240 (2016). - PubMed - DOI

MeSH terms

Substances